TherapeuticsMD (TXMD) Tops Q1 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- Goldman Sachs tech conference highlights AI spending outlook
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
TherapeuticsMD Announces First Quarter 2021 Financial Results
May 6, 2021 7:00 AM EDT- 1Q21 total net revenue increased to $19.9 million -
- 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 -
- ANNOVERA prescriptions continue to grow with increasing consumer support and acceptance -
- Further strengthened ANNOVERA® patent family through June 2039
- Significantly improved average net revenue per unit for IMVEXXY® to $61 and BIJUVA® to $69 -
-vitaCares divesture process continues in an effort to unlock shareholder value-
- Conference call scheduled... More
